S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 20, 2005
February 3, 2025
816481d6-42de-481e-8388-3a53fc8330cc
Related Documents
E2E Pharmacovigilance Planning
Guidance DocumentApril 1, 2005Center for Drug Evaluation and Research
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs
Guidance DocumentOctober 11, 2005Center for Drug Evaluation and Research
S8 Immunotoxicity Studies for Human Pharmaceuticals
Guidance DocumentApril 12, 2006Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox